Safety of combined targeted and helixor® viscum album l. therapy in breast and gynecological cancer patients, a real-world data study

HIGHLIGHTS

• who: Friedemann Schad and Anja Thronicke from the Network Oncology, Research Institute Havelhu00f6he, Kladower Damm, Berlin, Germany have published the article: Safety of Combined Targeted and Helixoru00ae Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study, in the Journal: (JOURNAL)
• what: The aim of this real-world data study was to determine the safety profile of targeted therapy in combination with add-on Methods:

SUMMARY

Targeted therapy as the foundation for precision medicine consists of small_molecules or monoclonal_antibodies that aim to inhibit or induce proteins . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.